ADC Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesBusiness Wire • 02/28/23
ADC Therapeutics to Host Fourth Quarter and Year-End 2022 Financial Results Conference Call on February 28, 2023Business Wire • 02/21/23
ADC Therapeutics Announces Pricing of Underwritten Offering by a Selling ShareholderBusiness Wire • 02/02/23
Wall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a BetZacks Investment Research • 01/16/23
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?Zacks Investment Research • 01/13/23
ADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/23
ADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaBusiness Wire • 12/21/22
FREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTSPRNewsWire • 12/12/22
ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/08/22
ADC Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesBusiness Wire • 11/08/22
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual MeetingBusiness Wire • 11/03/22
IGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin's LymphomaBusiness Wire • 11/02/22
ADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal OfficerBusiness Wire • 11/01/22
ADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022Business Wire • 10/31/22
Down 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)Zacks Investment Research • 10/12/22
Down 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a TurnaroundZacks Investment Research • 10/11/22
ADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)Business Wire • 09/21/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ADC Therapeutics SA - ADCTNewsfile Corp • 09/18/22